|
24 Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44(7):31863193
25 Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133(1):7077
26 Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest
Ophthalmol Vis Sci 2005;46(2):726733
27 Rosenfeld PJ, Brown DM, HeierJS, et al. Ranibizumab For neovascular agerelated macular degeneration. N Engl J Med 2006;355(14):14191431
28 Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355(14): 14321444
29 Heier JS, Boyer DS, Ciulla TA, et al. for the FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular agerelated macular degeneration: Year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124(11): 15321542
30 Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with centerinvolving clinically significant diabetic macular edema. Ophthalmology 2006; 113(10):17061712
31 Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular agerelated macular degeneration twelveweek results of an uncontrolled openlabel clinical study. Ophthalmology 2005;112(6):10351047
32 Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002;160(2):501509
33 Rich RM, Rosenfeld PJ, Puliafito CA, et al. Shortterm safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina 2006;26(5):495511
34 Avery RL,Pieramici DJ,Rabena MD, et al. Intravitreal bevacizumab (Avastin)for neovascular agerelated macular degeneration. Ophthalmology 2006;113(3): 363372
35 Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular agerelated macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36(4): 331335
36 Moschos MM, Brouzas D, Apostolopoulos M, et al. Intravitreal use of vevacizumab(Avastin) for choroidal neovascularization due to ARMD:A preliminary multifocalERG and OCT study:MultifocalERG after use of vevacizumab in ARMD. Doc Ophthalmol 2007; 114(1):3744
37 Saishin Y, Saishin Y, Takahashi K, et al. VEGFTRAP(R1R2) suppresses choroidal neovascularization and VEGFinduced breakdown of the bloodretinal barrier. J Cell Physiol 2003;195(2):241248
38 Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trapeye in patients with neovascular agerelated macular degeneration. Ophthalmology 2009;116(11):21412148
39 Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13(3):225234
40 Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular agerelated macular degeneration. Expert Opin Investig Drugs 2009;18(5):637646
41 Rota R, Riccioni T, Zaccarini M, et al. Marked inhibition of retinal neovascularization in rats following solubleflt1 gene transfer. J Gene Med 2004;6(9):9921002
42 Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8(2):128135
43 Dejneka NS, Kuroki AM, Fosnot J, et al. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004;10:964972
44 Holekamp N, Bouck N, Volpert O. Pigment epitheliumderived factor is deficient in the vitreous of patients with choroidal neovascularization due to agerelated macular degeneration. Am J Ophthalmol 2002;134(2):220227
45 Apte RS, Barreiro RA, Duh E, et al. Stimulation of neovascularization by the antiangiogenic factor PEDF. Invest Ophthalmol Vis Sci 2004;45(12):44914497
46 Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol. An openlabel, phase I, single administration, doseescalation study of ADGVPEDF.11D (ADPEDF) in neovascular agerelated macular degeneration (AMD). Hum Gene Ther 2001;12(16):20292032
47 Campochiaro PA, Nguyen QD, Shah, et al. Adenoviral vectordelivered pigment epitheliumderived factor for neovascular agerelated macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17(2):167176
48 Seo DW, Li H, Guedez L, et al. TIMP2 mediated inhibition of angiogenesis: an MMPindependent mechanism. Cell 2003;114(2):171180
49 Takahashi T, Nakamura T, Hayashi A, et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases3 in retinal pigment epithelium cells. Am J Ophthalmol 2000;130(6):774781
50 Campochiaro PA. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004;45(3):922931
51 Aiello LP, Clermont A, Arora V, et al. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetesinduced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006;47(1):8692
52 Maier P, Unsoeld AS, Junker B, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemiainduced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 2005;243(6):593600
53 Kramerov AA, Saghizadeh M, Pan H, et al. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am J
Pathol 2006;168(5):17221736
54 Dorrell MI, Aguilar E, Scheppke L, et al. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad
Sci USA 2007;104(3):967972 上一页 [1] [2] [3] |
